Bristol Myers Squibb (CELG-RI) Debt to Equity (2009 - 2026)

Bristol Myers Squibb has disclosed Debt to Equity across 18 years of filings, most recently posting $2.22 for Q1 2026.

• In Q1 2026, Debt to Equity fell 98.7% year-over-year to $2.22; the TTM figure through Mar 2026 stood at $2.22 (down 98.7% YoY), while the FY2025 annual figure was $2.44, down 26.66% from the prior year.
• Debt to Equity retreated to $2.22 in Q1 2026, from $2.44 in the prior quarter.
• Over the last five years, Debt to Equity for CELG-RI reached as high as $910.83 in Q2 2025 and fell as low as -$46.49 in Q3 2022.
• The 5-year median for Debt to Equity is $2.44 (2025), against an average of $126.94.
• The widest YoY moves for Debt to Equity: up 65455.05% in 2022, down 4702.23% in 2022.
• A 5-year view of Debt to Equity shows it stood at -$30.69 in 2022, then grew by 16.19% to -$25.73 in 2023, then surged by 112.94% to $3.33 in 2024, then fell by 26.66% to $2.44 in 2025, then dropped by 9.28% to $2.22 in 2026.
• According to Business Quant data, Debt to Equity over the past three periods registered $2.22, $2.44, and $2.63 for Q1 2026, Q4 2025, and Q3 2025 respectively.